CDDF Annual Conference – Day 3
Closing the Annual Conference 2023, we would like to thank all our stakeholders for their engagement and support for our shared mission to improve effective cancer treatment and empower patients. For those interested in our discussion during the last session,...
CDDF Annual Conference 2023 – Day 2
We invite you to take a look at the take-home messages and next steps from yesterday's sessions. SESSION 3: WHAT I SHOULD HAVE ASKED WHEN I STARTED MY CARREER IN CANCER DRUG DEVELOPMENT ❇ Take-Home Messages • It is important to consider where you want your career to...
CDDF Annual Conference 2023 – Day 1
Cancer Drug Development Forum (CDDF) opened the Annual Conference 2023 yesterday with more than 150 people joining onsite and online. Here are the Take-Home Messages from the first day of the Annual Conference: • Diversity can be understood as the combination of...
World Cancer Day – Closing the Gap in Cancer Care
Ahead of World Cancer Day (4 February 2023), the Cancer Drug Development Forum (CDDF) would like to turn the spotlight on existing inequalities in cancer care. To improve cancer patients’ equitable access to effective, innovative medicines, the CDDF is fully committed...
![[Publication] CDDF’s Meeting Report – Histology Independent Drug Development: Is This Future for Cancer Drugs?](https://cddf.org/wp-content/uploads/2023/01/Nov-Workshop_Meeting-Report_Social-Media-400x250.jpg)
[Publication] CDDF’s Meeting Report – Histology Independent Drug Development: Is This Future for Cancer Drugs?
The CDDF’s meeting report from its multi-stakeholder workshop on Histology independent drug development (Nov 2022, NL) has been published today. Discover thought-provoking key takeaways from the interesting sessions and share your thoughts with the CDDF community. To...
Season’s Greetings & Happy Holiday Wishe
🔔⛄ Season's Greetings & Happy Holiday Wishes from the CDDF to all cancer patients, their families, and our stakeholders: In warm appreciation of your support and engagement with the CDDF during the past year, the CDDF extends our very best wishes for a Happy...
New Publication: Prof. Mark Lawler (CDDF Board) & his colleagues – the Lancet Oncology European Groundshot Commission on cancer research
Prof. Mark Lawler (CDDF Board) & his colleagues in the Lancet Oncology European Groundshot Commission on cancer research have published an insightful article on 16 November 2022. The European Groundshot—addressing Europe’s cancer research challenges: a Lancet...
CDDF Appoints New Chairperson: A Warm Welcome to Ruth Plummer in this Role & a Fond Farewell to John Smyth and Francesco De Lorenzo
The Cancer Drug Development Forum (CDDF) are pleased to announce and welcome Professor Ruth Plummer as the new chairperson of the CDDF from 28 November 2022 for a three-year term. Professor Plummer replaces Professor John Smyth in this role. Professor Plummer has been...
Cancer World publication: Mark Lawler comments on the conclusions of a UK consensus group
The article on “UK consensus group calls for biomarker testing at point of diagnosist” has been published in the Cancer World online magazine (Sep, 2022). In the article, Mark Lawler (CDDF, UK), comments on the consensus statement, saying, “I welcome the conclusions...